Cancer immunotherapy has emerged as a revolutionary approach in the treatment of various malignancies, harnessing the power of the immune system to target and eliminate cancer cells. Among the innovative strategies within this field, Bispecific T-cell Engagers (BiTEs) represent a cutting-edge technology designed to recruit and activate T-cells, the body's primary immune effector cells, to specifically target and kill tumor cells. BiTEs exemplify the concept of redirecting the immune system's intrinsic capabilities toward malignant cells by leveraging the specificity of antibodies and the potent cytotoxic functions of T-cells.
Bispecific T-cell Engagers (BiTEs) are a type of immunotherapy designed to redirect T-cells to tumor cells, facilitating targeted cytotoxicity. This approach leverages the specificity of antibodies and the potent effector functions of T-cells to achieve anti-tumor effects.
What are BiTEs?
BiTEs are engineered proteins that belong to the class of bispecific antibodies, characterized by their ability to simultaneously bind to two different antigens. This dual specificity is achieved by constructing a single-chain variable fragment (scFv) from two monoclonal antibodies. The first scFv is specific for CD3, a component of the T-cell receptor (TCR) complex, and the second scFv targets a tumor-associated antigen (TAA) present on cancer cells. The result is a bispecific molecule that can physically bridge T-cells and tumor cells, facilitating a targeted immune response.
Share this post